Printer Friendly

Astra Zenaca signs cancer drug contract with Daiichi Sankyo.

M2 EQUITYBITES-April 1, 2019-Astra Zenaca signs cancer drug contract with Daiichi Sankyo


United Kingdom-based AstraZeneca has signed a contract with Japan-based Daiichi Sankyo, it was reported on Friday.

According to the global development and commercialisation collaboration, both firms will develop and commercialise trastuzumab deruxtecan (DS-8201), which is an antibody-drug conjugate and potential new targeted medicine for cancer treatment. The partnership is in line with AstraZeneca's science-led strategy in oncology and based on four crucial scientific platforms, which are tumour drivers and resistance, DNA damage response, immuno-oncology and antibody drug conjugate. Daiichi Sankyo will hold exclusive rights for the treatment in Japan and will also take responsibility for manufacturing and supply.

The deal is valued at USD6.9bn. Under the terms of the contract, Daiichi Sankyo will secure an upfront payment of USD1.35bn from AstraZeneca. The deal also includes contingent payments of up to USD5.55bn, including USD3.8bn for potential successful achievement of future regulatory and other milestones and USD1.75bn for sales-related milestones.

((Comments on this story may be sent to

COPYRIGHT 2019 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:Apr 1, 2019
Previous Article:Centre Partners closes acquisition of majority stake in One World Fitness.
Next Article:Blue Sprig Pediatrics closes acquisition of assets of Tangible Difference Learning Centre.

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters